Substantia nigra hyperechogenicity as a marker for Parkinson's disease: A population-based study

Neurodegenerative Diseases

Volumn 12, Issue 4, 2013, Pages 212-218

  Mahlknecht, Philipp ^a   Seppi, Klaus ^a   Stockner, Heike ^a   Nocker, Michael ^a   Scherfler, Christoph ^a   Kiechl, Stefan ^a   Willeit, Johann ^a   Schmidauer, Christoph ^a   Gasperi, Arno ^b   Rungger, Gregorio ^b   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Hospital of Bruneck   (Italy)

Author keywords

Biomarker; Diagnostic accuracy; General community; Neuroimaging; Parkinson's disease; Substantia nigra hyperechogenicity

Indexed keywords

AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; GEOGRAPHIC ORIGIN; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PARKINSON DISEASE; PARKINSONISM; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOM SAMPLE; SUBSTANTIA NIGRA; TRANSCRANIAL SONOGRAPHY;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; COMMUNITY HEALTH PLANNING; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; ROC CURVE; SEX FACTORS; SUBSTANTIA NIGRA; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84887123001     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000348595     Document Type: Article

References (41)

1. Gaenslen A, Unmuth B, Godau J, Liepelt I, Di SA, Schweitzer KJ, et al: The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008; 7: 417-424.
2. Berg D, Godau J, Walter U: Transcranial sonography in movement disorders. Lancet Neurol 2008; 7: 1044-1055.
3. Berg D, Merz B, Reiners K, Naumann M, Becker G: Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005; 20: 383-385.
4. Berg D, Siefker C, Becker G: Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001; 248: 684-689.
5. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R: Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease. Mov Disord 2007; 22: 48-54.
6. Busse K, Heilmann R, Kleinschmidt S, Abu-Mugheisib M, Hoppner J, Wunderlich C, et al: Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease. J Neurol Neurosurg Psychiatry 2012; 83: 441-447.
7. Walter U, Dressler D, Probst T, Wolters A, Abu-Mugheisib M, Wittstock M, et al: Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 2007; 64: 1635-1640.
8. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, et al: Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999; 53: 1026-1031.
9. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G: Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001; 56: 13-17.
10. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, et al: Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005.
11. Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, et al: In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005; 20: 1278-1285.
12. Wenning GK, Kiechl S, Seppi K, Muller J, Hogl B, Saletu M, et al: Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005; 4: 815-820.
13. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al: Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.
14. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
15. Schrag A, Ben-Shlomo Y, Quinn NP: Crosssectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 2000; 321: 21-22.
16. Berg D, Seppi K, Liepelt I, Schweitzer K, Wollenweber F, Wolf B, et al: Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 2010; 25: 1464-1469.
17. Stockner H, Iranzo A, Seppi K, Serradell M, Gschliesser V, Sojer M, et al: Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009; 24: 1906-1909.
18. Mahlknecht P, Stockner H, Nocker M, Kiechl S, Willeit J, Scherfler C, et al: A follow-up study of substantia nigra echogenicity in healthy adults. Mov Disord 2012; 27: 1196-1197.
19. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86: 420-428.
20. Mahlknecht P, Stockner H, Kiechl S, Willeit J, Rastner V, Gasperi A, et al: Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease? Mov Disord 2012; 27: 1194-1196.
21. Behnke S, Double KL, Duma S, Broe GA, Guenther V, Becker G, et al: Substantia nigra echomorphology in the healthy very old: correlation with motor slowing. Neuroimage 2007; 34: 1054-1059.
22. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R: Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007; 130: 1799-1807.
23. Stockner H, Schwingenschuh P, Djamshidian A, Silveira-Moriyama L, Katschnig P, Seppi K, et al: Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease? Mov Disord 2012; 27: 1182-1185.
24. von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, et al: Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473-490.
25. Taylor KS, Cook JA, Counsell CE: Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 905-906.
26. Spiegel J, Hellwig D, Mollers MO, Behnke S, Jost W, Fassbender K, et al: Transcranial sonography and [ 123 I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006; 129: 1188-1193.
27. Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM: Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease. Mov Disord 2007; 22: 550-555.
28. Stockner H, Sojer M, Seppi K, Mueller J, Wenning GK, Schmidauer C, et al: Midbrain sonography in patients with essential tremor. Mov Disord 2007; 22: 414-417.
29. Walter U, Wittstock M, Benecke R, Dressler D: Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002; 109: 191-196.
30. van de Loo S, Walter U, Behnke S, Hagenah J, Lorenz M, Sitzer M, et al: Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 1087-1092.
31. Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K: Neuroimaging: current role in detecting pre-motor Parkinson's disease. Mov Disord 2012; 27: 634-643.
32. Go CL, Frenzel A, Rosales RL, Lee LV, Benecke R, Dressler D, et al: Assessment of substantia nigra echogenicity in German and Filipino populations using a portable ultrasound system. J Ultrasound Med 2012; 31: 191-196.
33. Altman DG, Bland JM: Diagnostic tests 2: predictive values. BMJ 1994; 309: 102.
34. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870.
35. Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, et al: Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1, 847 older persons. Arch Neurol 2011; 68: 932-937.
36. Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, et al: Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013; 28: 216-219.
37. de Lau LM, Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-535.
38. Fahn S: Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003; 991: 1-14.
39. Berg D, Marek K, Ross GW, Poewe W: Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012; 27: 656-665.
40. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ: What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.
41. Hughes AJ, Daniel SE, Lees AJ: Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-1499.